Current Rheumatology Reports

, Volume 2, Issue 1, pp 53–61

Glucocorticoid-induced osteoporosis

  • Pauline Boulos
  • George Ioannidis
  • Jonathan D. Adachi
Article

Abstract

This article attempts to evaluate the results of several recently published clinical trials of drugs used in the treatment and prevention of glucocorticoid-induced osteoporosis. Despite our lack of understanding regarding the biological mechanisms that lead to glucocorticoid-induced bone loss, effective therapy has been developed. Bisphosphonates have demonstrated significant treatment benefits and should be considered the therapy of choice for both the treatment and prevention of glucocorticoid-induced osteoporosis.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Cushing H: The basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 1932, 50:137–195.Google Scholar
  2. 2.
    Adinoff A, Hollister JR: Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983, 309:265–268.PubMedCrossRefGoogle Scholar
  3. 3.
    Baylink DJ: Glucocorticoid-induced osteoporosis. N Engl J Med 1983, 309:306–308.PubMedCrossRefGoogle Scholar
  4. 4.
    Mulder H, Struys A: Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Brit J Rheumatol 1994, 33:348–350.CrossRefGoogle Scholar
  5. 5.
    Ip M, Lam K, Yam L, et al.: Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994, 105:1722–1727.PubMedCrossRefGoogle Scholar
  6. 6.
    Pearce G, Tabensky DA, Delmas PD, et al.: Corticosteroidinduced bone loss in men. J Clin Endocrinol Metab 1998, 83:801–806.PubMedCrossRefGoogle Scholar
  7. 7.
    Aman S, Hakala M, Silvennoinen J, et al.: Low incidence of osteoporosis in a two year follow-up of early community based patients with rheumatoid arthritis. Scand J Rheumatol 1998, 27:188–193.PubMedCrossRefGoogle Scholar
  8. 8.
    Kroger H, Honkanen R, Saarikoski S: Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann Rheum Dis 1994, 53:18–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Hosking DJ: Effects of corticosteroids on bone turnover. Respir Med 1993, 87(suppl A):15–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Suzuki Y, Ichikawa Y, Saito E, et al.: Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metab Clin Exper 1983, 32:151–156.Google Scholar
  11. 11.
    Sambrook PN, Kelly PJ, Fontana D, et al.: Mechanisms of rapid bone loss following cardiac transplantation. Osteoporos Int 1994, 4:273–276.PubMedCrossRefGoogle Scholar
  12. 12.
    Wong MM, Rao LG, Ly H, et al.: Long-term effects of physiologic concentrations of dexamethasone on human bone-derived cells. J Bone Miner Res 1990, 5:813.Google Scholar
  13. 13.
    Chavassieux P, Pastorneau PCM, et al.: Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int 1993, 3:97–102.PubMedCrossRefGoogle Scholar
  14. 14.
    Canalis E: Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996, 81:3441–3447.PubMedCrossRefGoogle Scholar
  15. 15.
    Verstraeten A, Dequeker J: Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986, 45:852–857.PubMedCrossRefGoogle Scholar
  16. 16.
    Gough AK, Lilley J, Eyre S, et al.: Generalized bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344:27.CrossRefGoogle Scholar
  17. 17.
    Sambrook P, Birmingham J, Kempler S, et al.: Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 1990, 5:1211–1216.PubMedGoogle Scholar
  18. 18.
    LoCascio V, Bonucci E, Imbimbo G: Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990, 8:39–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Laan RF, van Riel PL, van de Putte LB, et al.: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993, 119:963–968.PubMedGoogle Scholar
  20. 20.
    Storm T, Thamsborg G, Steiniche T, et al.: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990, 322:1265–1271.PubMedCrossRefGoogle Scholar
  21. 21.
    Watts NB, Harris ST, Genant HK, et al.: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73–79.PubMedCrossRefGoogle Scholar
  22. 22.
    Black DM, Cummings SR, Karpf DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996, 348:1535–1541.PubMedCrossRefGoogle Scholar
  23. 23.
    Liberman UA, Weiss SR, Broll J, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437–1443.PubMedCrossRefGoogle Scholar
  24. 24.
    Devogelaer JP, Broll K, O, Orrea-Rotter R, et al.: Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996, 18:141–150.PubMedCrossRefGoogle Scholar
  25. 25.
    Tucci JR, Tonino RP, Emkey RD: Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996, 101:488–501.PubMedCrossRefGoogle Scholar
  26. 26.
    Amin S, LaValley MP, Simms RW, et al.: A meta-analysis ranking efficacy of treatments for corticosteroid-induced osteoporosis (CSOP). Arthritis Rheum 1998, 41(suppl):S137.Google Scholar
  27. 27.
    Adachi JD, Bensen WG, Brown J, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382–387. First randomized controlled study of etidronate in the prevention of glucocorticoid-induced osteoporosis that demonstrated fracture benefit. The fracture benefit was seen primarily in post-menopausal women.PubMedCrossRefGoogle Scholar
  28. 28.
    Roux C, Oriente P, Laan R, et al.: Randomized trial of effect of cyclical etidronate in the prevention of corticosteroidinduced bone loss: Ciblos Study Group. J Clin Endocrinol Metab 1998, 83:1128–1133.PubMedCrossRefGoogle Scholar
  29. 29.
    Wolfhagen FH, van Buuren HR, den Ouden JW, et al.: Cyclical etidronate in the prevention of bone loss in corticosteroidtreated primary biliary cirrhosis: a prospective, controlled pilot study. J Hepatol 1997, 26:325–330.PubMedCrossRefGoogle Scholar
  30. 30.
    Jenkins EA, Walker-Bone KE, Wood A, et al.: The prevention of corticosteroid induced osteoporosis with intermittent cyclical etidronate. Bone 1997, 20(suppl):103S.Google Scholar
  31. 31.
    Boutsen Y, Jamart J, Esselinckx W, et al.: Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 1997, 61:266–271.PubMedCrossRefGoogle Scholar
  32. 32.
    Gonnelli S, Rottoli P, Cepollaro C, et al.: Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997, 61:382–385.PubMedCrossRefGoogle Scholar
  33. 33.
    Cohen S, Levy R, Keller M, et al.: Risedronate prevents bone loss and decreases the risk of vertebral fractures in corticosteroid-induced osteoporosis. Bone 1998, 23:S595.Google Scholar
  34. 34.
    Nordborg E, Schaufelberger C, Andersson R, et al.: The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid-treated patients with giant-cell arteritis. J Intern Med 1997, 242:367–371.PubMedCrossRefGoogle Scholar
  35. 35.
    Saag KG, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292–299. Largest randomized controlled study of alendronate in the treatment of glucocorticoid-induced osteoporosis. The first study to show increases in bone mineral density, with alendronate therapy, at the spine, hip and whole body. Fracture benefit was also seen in postmenopausal women.PubMedCrossRefGoogle Scholar
  36. 36.
    Saag K, Emkey R, Cividino A, et al.: Effects of alendronate for two years and BMD and fractures in patients receiving glucocorticoids. Bone 1998, 23:S182.Google Scholar
  37. 37.
    Pitt P, Li F, Todd P, et al.: A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax 1998, 53:351–356.PubMedCrossRefGoogle Scholar
  38. 38.
    Guesens P, Vanhoof J, Stalmans R, et al.: Cyclic etidronate increases bone density in the spine and hip in postmenopausal women on chronic corticosteroid treatment. Bone 1997, 20(suppl):9S.Google Scholar
  39. 39.
    Reid D, Cohen S, Pack S, Chines A, et al.: Risedronate is an effective and well-tolerated therapy in both the treatment and prevention of corticosteroid-induced osteoporosis. Bone 1998, 23:S402. Although the study is reported as an abstract, this is the first randomized controlled study to show the risedronate was effective in the prevention and treatment of glucocorticoid-induced osteoporosis. The pooled results of both the prevention and treatment studies indicated fracture benefit in patients receiving risedronate therapy.Google Scholar
  40. 40.
    Adachi JD, Pack S, Chines A: Intermittent etidronate and corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:1921.CrossRefGoogle Scholar
  41. 41.
    Adachi JD, Bensen WG, Bell MJ, et al.: Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997, 36:255–259.PubMedCrossRefGoogle Scholar
  42. 42.
    Lems WF, Jacobs WG, Bijlsma JW, et al.: Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int 1997, 7:575–582.PubMedCrossRefGoogle Scholar
  43. 43.
    Lems WF, Jacobs JW, Bijlsma JW, et al.: Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis 1997, 56:357–363. The first randomized controlled study to suggest that there may be an added benefit for the spine in using fluoride in combination with an antiresorptive agent.PubMedCrossRefGoogle Scholar
  44. 44.
    Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627–1633. The first randomized controlled study of human parathyroid hormone in the treatment of glucocorticoid-induced osteoporosis. Results indicated differences between groups in bone mineral density at the lumbar spine, in favour of human parathyroid hormone therapy.PubMedCrossRefGoogle Scholar
  45. 45.
    Hall GM, Daniels M, Doyle DV, et al.: Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994, 37:1499–1505.PubMedCrossRefGoogle Scholar
  46. 46.
    Reid IR, Wattie DJ, Evans MC, et al.: Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996, 156:1173–1177.PubMedCrossRefGoogle Scholar
  47. 47.
    Delmas PD, Bjarnason NH, Mitlak BH, et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641–1647.PubMedCrossRefGoogle Scholar
  48. 48.
    Reginster JY, Kuntz D, Verdickt W, et al.: Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999, 9:75–81.PubMedCrossRefGoogle Scholar
  49. 49.
    Sambrook P, Birmingham J, Kelly P, et al.: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993, 328:1747–1752.PubMedCrossRefGoogle Scholar
  50. 50.
    Buckley LM, Leib ES, Cartularo KS, et al.: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 125:961–968.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Pauline Boulos
    • 1
  • George Ioannidis
    • 1
  • Jonathan D. Adachi
    • 1
  1. 1.St. Joseph’s Hospital, McMaster UniversityHamiltonCanada

Personalised recommendations